Allan James

A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma

R. Rampling, Sharon Peoples, Paul Mulholland et al. · Clinical Cancer Research · 2016 · 160 citations · Full text

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

Ben Fulton, Susan Short, Allan James et al. · Clinical and Translational Radiation Oncology · 2017 · 62 citations · Full text

Health economic evaluation of a serum-based blood test for brain tumour diagnosis: exploration of two clinical scenarios

Ewan Gray, Holly J. Butler, Ruth Board et al. · BMJ Open · 2018 · 54 citations · Full text

12 week PET-CT has low positive predictive value for nodal residual disease in human papillomavirus-positive oropharyngeal cancers

R. Rulach, Suyun Zhou, Fraser Hendry et al. · Oral Oncology · 2019 · 46 citations

Week Pet-ct, Medicine, Pathology +8

Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.

Anthony J. Chalmers, Susan Short, Colin Watts et al. · Journal of Clinical Oncology · 2018 · 35 citations

Parp Inhibitor Combinations, Elderly Gbm, Pharmacotherapy +22